WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H461872
CAS#: 96914-39-5
Description: Actisomide is an antiarrhythmic drug.
Hodoodo Cat#: H461872
Name: Actisomide
CAS#: 96914-39-5
Chemical Formula: C23H35N3O
Exact Mass: 369.28
Molecular Weight: 369.550
Elemental Analysis: C, 74.75; H, 9.55; N, 11.37; O, 4.33
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Actisomide; Actisomidum; SC 36602; SC-36602; SC36602;
IUPAC/Chemical Name: (4R,4aR)-4-(2-(diisopropylamino)ethyl)-1-methyl-4-phenyl-4,4a,5,6,7,8-hexahydro-3H-pyrido[1,2-c]pyrimidin-3-one
InChi Key: QAHRRCMLXFLZTF-FYYLOGMGSA-N
InChi Code: InChI=1S/C23H35N3O/c1-17(2)25(18(3)4)16-14-23(20-11-7-6-8-12-20)21-13-9-10-15-26(21)19(5)24-22(23)27/h6-8,11-12,17-18,21H,9-10,13-16H2,1-5H3/t21-,23-/m1/s1
SMILES Code: O=C1[C@@](C2=CC=CC=C2)(CCN(C(C)C)C(C)C)[C@](CCCC3)([H])N3C(C)=N1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 369.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Mahmood I. Prediction of clearance, volume of distribution and half-life by allometric scaling and by use of plasma concentrations predicted from pharmacokinetic constants: a comparative study. J Pharm Pharmacol. 1999 Aug;51(8):905-10. PubMed PMID: 10504028.
2: Cook CS, Rozek LF, Stolzenbach J, Anderson S, Schoenhard GL, Karim A. Pharmacokinetics of a novel antiarrhythmic drug, actisomide. Pharm Res. 1993 Mar;10(3):427-33. PubMed PMID: 8464818.
3: Cook CS, Rozek LF, Hribar J, Schoenhard GL, Karim A. Metabolism of actisomide in the dog, monkey and man: a novel rearrangement of N-dealkylated metabolites. Eur J Drug Metab Pharmacokinet. 1992 Apr-Jun;17(2):145-54. PubMed PMID: 1425813.
4: Malesker MA, Mohiuddin SM, Destache CJ, Stoysich A, Dean RR, Hilleman DE, Sketch MH Sr. Pharmacokinetic and tolerance evaluation of actisomide, a new antiarrhythmic agent, in healthy volunteers. DICP. 1991 Mar;25(3):231-4. PubMed PMID: 2028626.
